| 摘要 |
<p>Process and novel intermediates for preparing the L-monovaline ester of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol and its pharmaceutically acceptable salts. The present process and intermediates provide for reduced impurities in the mono-valine ester end-product, also eliminating the costly and time consuming purification step and allowing the use of starting materials of lower purity, which, in turn, reduces overall production costs. These products are of value as antiviral agents with improved absorption.</p> |
